title: Impact of interleukin-10, soluble CD25 and interferon-γ on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study.
abstract: BACKGROUND
  The pathophysiology of sepsis consists of two phases. A first phase characterized by a substantial increase of pro-inflammatory mediators including cytokines and systemic inflammatory markers, and a second phase (immunoparalysis, immunodysregulation) associated with the rise of anti-inflammatory mediators. In this study we prospectively analyzed 52 consecutive patients with diagnosis of systemic inflammatory response syndrome (SIRS) at hospital admission to evaluate prognostic and early diagnostic performance of interleukin-10 (IL-10), soluble CD25 (sCD25) and interferon-γ (IFN-γ) and to confirm the prognostic accuracy of the sequential organ failure assessment (SOFA) score.
  
  
  METHODS
  Patients were divided in two groups (group 1, n=28 patients with bacteremic SIRS and group 2, n=24 patients with non-bacteremic SIRS) and then stratified into survivors (n=39) and nonsurvivors (n=13). Serum markers were evaluated on the day of hospital admission (D-1) and on the 7th day of hospital stay (D-7). Concentration of sCD25 was evaluated by a sandwich ELISA kit. Levels of IL-10 and IFN-γ were quantified by a cytokine biochip array by the evidence investigator analyzer. Differences between groups were established by the Mann-Whitney test. Accuracy, sensitivity and specificity of diagnostic markers were evaluated by the receiver-operating characteristic curve analysis. Multivariate analysis was carried out to evaluate whether studied biomarkers are independent predictors of poor outcome in prognosis, and of bacteremic SIRS in diagnosis.
  
  
  RESULTS
  IL-10, sCD25 and SOFA scores of survivors and nonsurvivors were significantly different both at D-1 (P=0.0014; P=0.014 and P=0.0311 respectively) and at D-7 (P=0.0002, P=0.014 and P=0.0012 respectively). Between the above groups IFN-γ level was significantly different only at D-7 (P=0.0013). Moreover IL-10 and sCD25 were significantly higher in bacteremic versus non-bacteremic SIRS patients at D-1 and at D-7 (P<0.05). IFN-γ values showed a significant decrease (P<0.05) in patients of group 1 only at D-7. The diagnostic accuracy of IL-10 and sCD25 was confirmed by the analysis of the AUROCC at D-1 and D-7 respectively. Multivariate analysis revealed that sCD25 and IL-10 are independent predictors of a poor outcome for our patients during the first day of hospital admission.
  
  
  CONCLUSIONS
  IL-10 and sCD25 gave a significant contribution to prognostic evaluation and early diagnosis of bacteremic SIRS. SOFA score appeared to be a reliable prognostic tool in this subset of patients.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Matera
authors.forename: Rossana
authors.initials: R
authors.lastname: Puccio
authors.forename: Aida
authors.initials: A
authors.lastname: Giancotti
authors.forename: Angela
authors.initials: A
authors.lastname: Quirino
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Pulicari
authors.forename: Emilia
authors.initials: E
authors.lastname: Zicca
authors.forename: Santo
authors.initials: S
authors.lastname: Caroleo
authors.forename: Attilio
authors.initials: A
authors.lastname: Renzulli
authors.forename: Maria Carla
authors.initials: MC
authors.lastname: Liberto
authors.forename: Alfredo
authors.initials: A
authors.lastname: Focà
mesh_terms: D000368:Aged; D016470:Bacteremia / Q000097:blood* / Q000175:diagnosis; D015415:Biomarkers / Q000097:blood; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood*; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood* / Q000175:diagnosis
chemical_list: D015415:Biomarkers; C508609:IL10 protein, human; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D016753:Interleukin-10; D007371:Interferon-gamma
references.citation: J Immunol. 2007 Jul 1;179(1):623-30
references.pmid: 17579084
references.citation: Physiol Res. 2000;49 Suppl 1:S57-61
references.pmid: 10984072
references.citation: Lancet. 1993 Feb 27;341(8844):515-8
references.pmid: 8094770
references.citation: Int J Health Geogr. 2010 Feb 15;9:9
references.pmid: 20156361
references.citation: Shock. 2010 Oct;34(4):377-83
references.pmid: 20610943
references.citation: Clin Infect Dis. 2003 Mar 15;36(6):825-6; author reply 826-7
references.pmid: 12627373
references.citation: J Biomed Inform. 2005 Oct;38(5):404-15
references.pmid: 16198999
references.citation: Mol Med. 2008 May-Jun;14(5-6):247-56
references.pmid: 18297128
references.citation: Am J Pathol. 2007 May;170(5):1435-44
references.pmid: 17456750
references.citation: Lancet. 2005 Jan 1-7;365(9453):63-78
references.pmid: 15639681
references.citation: J Leukoc Biol. 2004 Mar;75(3):400-7
references.pmid: 14557385
references.citation: Intensive Care Med. 1996 Jul;22(7):707-10
references.pmid: 8844239
references.citation: Mol Med. 2008 Jan-Feb;14(1-2):64-78
references.pmid: 18026569
references.citation: Shock. 2006 Dec;26(6):544-50
references.pmid: 17117127
references.citation: Crit Care Med. 2007 May;35(5):1244-50
references.pmid: 17414736
references.citation: Nat Rev Immunol. 2008 Jul;8(7):523-32
references.pmid: 18566595
references.citation: Clin Chest Med. 2008 Dec;29(4):617-25, viii
references.pmid: 18954697
references.citation: J Surg Res. 2008 Jun 1;147(1):1-8
references.pmid: 17720196
references.citation: Crit Care. 2010;14(1):R15
references.pmid: 20144219
references.citation: Acta Clin Belg. 2006 May-Jun;61(3):138-42
references.pmid: 16881563
references.citation: Am J Respir Crit Care Med. 2001 Aug 1;164(3):396-402
references.pmid: 11500339
references.citation: Shock. 2002 Dec;18(6):487-94
references.pmid: 12462554
references.citation: Nature. 2002 Dec 19-26;420(6917):885-91
references.pmid: 12490963
references.citation: Clin Infect Dis. 1998 Jul;27(1):185-90
references.pmid: 9675475
references.citation: Crit Care Med. 2008 Mar;36(3):941-52
references.pmid: 18431284
references.citation: J Leukoc Biol. 2008 Mar;83(3):471-82
references.pmid: 18171697
references.citation: Crit Care. 2004 Aug;8(4):R234-42
references.pmid: 15312223
references.citation: Intensive Care Med. 2002 Mar;28(3):235-43
references.pmid: 11904651
references.citation: Lancet Infect Dis. 2007 Mar;7(3):210-7
references.pmid: 17317602
references.citation: Tohoku J Exp Med. 2008 Sep;216(1):61-8
references.pmid: 18719339
references.citation: Eur Cytokine Netw. 2005 Sep;16(3):191-3
references.pmid: 16266858